Back to top
more

TCR2 THERAPTCS (TCRR)

(Delayed Data from NSDQ)

$16.92 USD

16.92
16,723

+0.13 (0.77%)

Updated May 3, 2019 04:13 PM ET

After-Market: $17.00 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

[TCRR]

Reports for Purchase

Showing records 1 - 20 ( 162 total )

Industry: Medical - Drugs

Record: 1

05/12/2023

Company Report

Pages: 4

Dropping Coverage of TCRR Ahead of Merger with ADAP

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 2

03/23/2023

Company Report

Pages: 5

Can These TRUCs ADAPt to Their New Environment?

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 3

03/07/2023

Company Report

Pages: 4

TCR2 Slated to Merge With Adaptimmune; Downgrading to Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 4

03/06/2023

Company Report

Pages: 7

TCR2 ADAPting for the Future

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 5

03/06/2023

Industry Report

Pages: 4

Event Driven A.M. Note

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 6

01/05/2023

Company Report

Pages: 5

Joins the New Year''s Diet Plans

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 7

11/21/2022

Company Report

Pages: 4

3Q22 Financials Reported; Modulating PT to $13

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 8

11/08/2022

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 9

11/08/2022

Company Report

Pages: 6

3Q22: Business Updates

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 10

11/08/2022

Company Report

Pages: 6

Keeps its TRuC-s Moving

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 11

11/07/2022

Daily Note

Pages: 8

E&P Update-Relative Value Tables

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 12

09/29/2022

Company Report

Pages: 4

Updated Phase 1 Gavo-Cel Results Remain Encouraging, in Our View; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 13

09/29/2022

Daily Note

Pages: 6

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 14

09/29/2022

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 15

09/28/2022

Company Report

Pages: 7

TCRR Delivers More Data Packages from the Gavo-cel TRuC

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 16

09/28/2022

Company Report

Pages: 8

Additional Solid Tumor Responses in Phase I Update. Phase II Ongoing.

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 17

09/23/2022

Daily Note

Pages: 10

HEALTHCARE- The Week Ahead in Life Sciences

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 18

09/16/2022

Daily Note

Pages: 10

HEALTHCARE- The Week Ahead in Life Sciences

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 19

08/29/2022

Industry Report

Pages: 10

The Week Ahead in Life Sciences

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 20

08/18/2022

Company Report

Pages: 4

A Catalyst-Rich 2H22; 2Q22 Financials; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 5.00

Research Provided by a Third Party
// eof